Medpace Holdings Inc (MEDP)
404.45
+4.36
(+1.09%)
USD |
NASDAQ |
May 07, 14:13
Medpace Holdings Enterprise Value: 11.99B for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 11.99B |
| May 03, 2024 | 11.76B |
| May 02, 2024 | 11.71B |
| May 01, 2024 | 11.92B |
| April 30, 2024 | 11.63B |
| April 29, 2024 | 11.99B |
| April 26, 2024 | 11.86B |
| April 25, 2024 | 11.67B |
| April 24, 2024 | 11.91B |
| April 23, 2024 | 12.21B |
| April 22, 2024 | 11.25B |
| April 19, 2024 | 11.12B |
| April 18, 2024 | 11.19B |
| April 17, 2024 | 11.44B |
| April 16, 2024 | 11.52B |
| April 15, 2024 | 11.59B |
| April 12, 2024 | 11.83B |
| April 11, 2024 | 12.06B |
| April 10, 2024 | 11.92B |
| April 09, 2024 | 12.13B |
| April 08, 2024 | 12.26B |
| April 05, 2024 | 12.01B |
| April 04, 2024 | 11.65B |
| April 03, 2024 | 11.87B |
| April 02, 2024 | 11.75B |
| Date | Value |
|---|---|
| April 01, 2024 | 11.92B |
| March 31, 2024 | 12.11B |
| March 28, 2024 | 12.28B |
| March 27, 2024 | 12.25B |
| March 26, 2024 | 12.23B |
| March 25, 2024 | 12.22B |
| March 22, 2024 | 12.42B |
| March 21, 2024 | 12.56B |
| March 20, 2024 | 12.03B |
| March 19, 2024 | 11.75B |
| March 18, 2024 | 11.78B |
| March 15, 2024 | 11.96B |
| March 14, 2024 | 12.20B |
| March 13, 2024 | 12.30B |
| March 12, 2024 | 12.29B |
| March 11, 2024 | 12.16B |
| March 08, 2024 | 12.23B |
| March 07, 2024 | 12.35B |
| March 06, 2024 | 12.37B |
| March 05, 2024 | 12.15B |
| March 04, 2024 | 12.13B |
| March 01, 2024 | 12.19B |
| February 29, 2024 | 11.98B |
| February 28, 2024 | 12.15B |
| February 27, 2024 | 12.17B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.947B
Minimum
Jun 03 2019
12.56B
Maximum
Mar 21 2024
5.540B
Average
5.490B
Median
Enterprise Value Benchmarks
| Charles River Laboratories International Inc | 14.51B |
| Avid Bioservices Inc | 645.21M |
| Iovance Biotherapeutics Inc | 3.601B |
| Renovaro Inc | 220.33M |
| Candel Therapeutics Inc | 245.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 102.59M |
| Revenue (Quarterly) | 511.04M |
| Total Expenses (Quarterly) | 406.98M |
| EPS Diluted (Quarterly) | 3.20 |
| Gross Profit Margin (Quarterly) | 30.36% |
| Profit Margin (Quarterly) | 20.07% |
| Earnings Yield | 2.43% |
| Operating Earnings Yield | 2.76% |
| Normalized Earnings Yield | 2.425 |